Acetylator Phenotype and Lupus Erythematosus
- 1 January 1981
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 6 (2) , 118-134
- https://doi.org/10.2165/00003088-198106020-00003
Abstract
There are several known therapeutic implications of acetylator phenotype; among them, the association of a higher incidence of procainamide- and hydralazine-induced lupus in slow acetylators....Keywords
This publication has 99 references indexed in Scilit:
- Antibodies to Nuclear Antigens in Patients Treated with Procainamide or AcetylprocainamideNew England Journal of Medicine, 1979
- Clinical Pharmacokinetics of IsoniazidClinical Pharmacokinetics, 1979
- Effect of Acetylator Phenotype on the Rate at Which Procainamide Induces Antinuclear Antibodies and the Lupus SyndromeNew England Journal of Medicine, 1978
- Disease and Acetylation PolymorphismClinical Pharmacokinetics, 1977
- Abnormal lymphocyte function is secondary to drug-induced autoimmunity.Annals of the Rheumatic Diseases, 1976
- Drug-Induced Antinuclear Antibodies and Lupus SyndromesDrugs, 1976
- Long-Term Use of Procaine Amide following Acute Myocardial InfarctionCirculation, 1973
- Anticonvulsant-induced antinuclear antibodiesand lupus-like disease in childrenThe Journal of Pediatrics, 1973
- Enzymic coupling of isoniazid to proteinsBiochemistry, 1972
- Granulocytopenia, lupus-like syndrome, and other complications of propylthiouracil therapyThe Journal of Pediatrics, 1970